Introduction {#s1}
============

Cisplatin is a non-specific alkylating agent used for decades to successfully treat various cancers. However, cisplatin has dose-dependent toxicity and resistance often develops ([@B1], [@B2]). Mitochondrial dynamics play an important role in resistance to chemotherapy and severity of side effects. Many anti-cancer medications can cause mitochondrial dysfunction and DNA damage, and cells depleted of mtDNA show increased resistance to chemotherapeutic agents. Cisplatin is a pro-apoptotic drug that damages mitochondria, contributing to the toxicities in gastrointestinal, auditory, and kidney proximal tubule cells ([@B3]--[@B5]). Cisplatin treatment of head and neck squamous cell carcinoma and Chinese hamster ovarian cells significantly increases adduct formation in mitochondrial (mt) DNA compared to nuclear (n) DNA ([@B6]). Furthermore, mtDNA is more likely to remain damaged after cisplatin exposure because mitochondria lack the nucleotide-excision repair mechanisms found in nDNA. The severity of cancer drug side effects and incidence of induced resistance to chemotherapy drugs vary amongst individuals but the mechanism(s) are still not fully understood.

Cisplatin side effects include nausea, vomiting, myelosuppression, nephrotoxicity, neurotoxicity, cognitive dysfunction retinopathy, and hearing loss. Intravenous delivery of cisplatin commonly causes mild to moderate pigmentary retinopathy, along with intra-retinal hemorrhages, exudates, and cotton wool spots ([@B7]). In addition, significant vision loss can occur with both systemic and local delivery methods of the drug ([@B7]). However, it is unclear which individuals are going to be susceptible to this toxicity. The decision to continue a drug regimen depends not only on the effectiveness in treating the malignancy, but also on a person\'s tolerance to the drug and the risks of end-organ damage. Thus, insight into the mechanisms of cisplatin toxicity is valuable to patient care and therefore, a model using human retinal pigment epithelial (RPE) cells was developed to study mechanisms of cytotoxic damage.

Mitochondria are unique organelles that play essential roles in ATP production, calcium homeostasis, apoptosis, and cell signaling. The mtDNA are maternally inherited and can be classified into different haplogroups based on patterns of single nucleotide polymorphisms (SNPs) that have accumulated over thousands of years. The mtDNA haplogroups represent populations from different geographic origins and subsequently, can be used to characterize different ethnic groups. Clinically, different ethnic populations show dissimilar susceptibilities to diseases and drug responses ([@B8]--[@B10]), and it has been suggested that mtDNA haplogroups may play important roles in these differences ([@B11]). Specific mtDNA haplogroups have also been associated with renal, prostate, breast, and lung cancers ([@B12]--[@B15]). In addition, somatic and germline mtDNA mutations, as well as levels of mtDNA copy numbers, have been associated with increased risk of cancer and different responses to anti-cancer drugs ([@B16]). These studies demonstrate how polymorphisms and/or variants in mtDNA can lead to significant changes at the molecular and cellular levels and can be associated with increased cancer risk.

One method to characterize the functional consequences of cells having specific mtDNA haplogroups is through transmitochondrial cybrids (cells with identical nuclei but different mtDNA). Previously, we demonstrated that H cybrids (Southern European maternal origin mtDNA) vs. J cybrids (Northern European maternal origin mtDNA) have significantly different cellular homeostasis. Although all cybrids had identical nuclei and culture conditions, cells containing the J mtDNA had increased rates of growth along with higher lactate and glycolysis levels, but showed significantly lower MT-RNA expression and ATP levels compared to the H cybrids ([@B17], [@B18]). Interestingly, even though the J cybrids were created in a non-cancerous human retinal cell line (ARPE-19), the behavior of these cells was characteristic of the *Warburg Effect*, which described cancerous cells to be more glycolytic, using less oxidative phosphorylation, and producing high amounts of lactate in the presence of oxygen (aerobic glycolysis).

Using a HeLa cybrid model, Amo et al. was able to demonstrate that resistance to cisplatin was conferred via alterations of the mtDNA within the control region and that cisplatin-resistant clones possessed shorter OriB variants within a 16184-16193 region enriched with cytosine repeats ([@B19]). Interestingly, alterations of the nuclear genome were not involved in the cisplatin resistance. These findings support the hypothesis that the SNP differences that define the different haplogroups would be important for the responses to cisplatin and as the H and J haplogroup populations possess disparate SNP patterns, then their cybrids would show different responses.

In the present study, we compared the effects of cisplatin on human RPE cell cybrids that possessed either H or J haplogroup mtDNA and found differential responses in levels of cell viability, reactive oxygen species production, mitochondrial membrane potential, and gene expression levels in pathways related to cell signaling, apoptosis, and cisplatin resistance.

Methods {#s2}
=======

Cybrid Creation
---------------

All subjects read and signed an informed consent (IRB \#2003-3131) from the Institutional Review Board of the University of California, Irvine. All clinical investigations and protocols were conducted according to the principles of the Declaration of Helsinki and approved by the appropriate investigational review boards (University of California, Irvine). Cybrids were generated as described previously ([@B17], [@B18]). H and J cybrids were created by polyethylene glycol fusion of platelets with the Rho*0* (mtDNA free) ARPE-19 cells, which had been treated by low dosage ethidium bromide as described by Miceli and Jazwinski ([@B20]). H and J cybrids were cultured to the fifth passage using DMEM-F12 containing 10% dialyzed fetal bovine serum, 100 unit/ml penicillin and 100 μg/ml streptomycin, 2.5 μg/ml fungizone, 50 μg/ml gentamycin, and 17.5 mM glucose. [Figure 1](#F1){ref-type="fig"} provides description of the background of the subjects used in this study. The ages for the H mtDNA subjects (*n* = 7 cybrids) were 30.57 ± 3.39 years old, while ages for the J mtDNA subjects (*n* = 7 cybrids) were 36.14 ± 5.47 years (*P* = 0.4) ([Figure 1A](#F1){ref-type="fig"}). There were 4 males and 3 females for the J haplogroup subjects and 5 males and 2 females in the H haplogroup subjects. [Figures 1B,C](#F1){ref-type="fig"} show the haplogroup defining SNPs in the mtDNA for the J cybrids and H cybrids used in this study (see sequencing method below).

![**(A)** Age and gender profiles for the J haplogroup (*n* = 7) and H haplogroup (*n* = 7) subjects. **(B)** Schematic derived from Haplogrep (<https://haplogrep.uibk.ac.at>) showing the SNPs that define the J mtDNA haplogroups for subjects used in this study. **(C)** Schematic derived from Haplogrep (<https://haplogrep.uibk.ac.at>) showing the SNPs that define the H mtDNA haplogroups for subjects used in the study. Red font, Haplogroup associated polymorphism missing. Green font, Polymorphisms associated with haplogroup.](fonc-09-00640-g0001){#F1}

Sequencing of mtDNA From H and J Cybrids
----------------------------------------

DNA was extracted from the individual cybrids (*n* = 7 for H cybrids and *n* = 7 for J cybrids) using a kit (DNeasy Blood and Tissue Kit, Qiagen, Germantown, MD). Next Generation Sequencing (NGS) technology that sequences both strands of mtDNA independently in both directions was used to quantitate the haplogroup-defining SNPs, private SNPs (not defining haplogroups), and low frequency heteroplasmy SNPs across the entire mitochondrial genome.

### NGS Sequencing

Primers were designed across the entire human mitochondrial genome. A total of 171 primer pairs were designed that overlapped each other to capture the intervening sequences. A total of 100 ng of DNA per sample was used to construct NGS libraries using the TruSeq Custom Amplicon kit (Illumina, San Diego, CA). Two independent sets of primer pools were synthesized. The two primer pools had primers that were complementary. The two primer pools would interrogate the two strands of the mitochondrial genome independently. The two independent libraries had 48 samples each. NGS sequencing was done using 96 libraries (for 48 samples X 2 pools) that were loaded in 2 lanes for a 2 × 225 run on a HiSeq instrument (Illumina). After sequencing, somatic variant analysis was carried out using the variant caller---Pisces ([@B21]). Variant calls from each pool were combined to get a list of "true" variants. True variants are defined as variants present on both strands of the DNA. The true variant list was used for final haplogroup analyses using Haplogrep (<http://haplogrep.uibk.ac.at>). Variants present on only one strand may represent DNA modification events or other artifacts especially at low frequency and therefore were eliminated from the final haplogroup analysis. This method is capable of deep sequencing (average sequencing depth of 30,000; range 1,000--100,000) and accurately differentiates low frequency mtDNA heteroplasmy SNPs from DNA modification artifacts. The amino acid changes and association with diseases resulting from some of the SNPs variants were verified using [www.MitoMap.org](http://www.MitoMap.org) ([@B22], [@B23]). In some cases, the [www.Phylotree.org](http://www.Phylotree.org) ([@B24]) was used to verify the positions of specific SNPs within the Haplogroup H or Haplogroup J, and also determine if the SNPs were elsewhere in the entire mtDNA tree Build 17. The rs numbers were identified using [www.ncbi.nlm.nih.gov/snp](http://www.ncbi.nlm.nih.gov/snp). The website [www.hmtvar.uniba.it](http://www.hmtvar.uniba.it), a database with over 40K human mtDNA variants ([@B25]), was utilized to search for specific variants using the Query Tab and inputting the SNP value into the Position field to determine Mutation, Amino Acid Change (if any), and Locus, as well as the link to external resources such as dbSNP for rs numbers. All of the SNPs identified had a Quality Score of 100 (A Phred-scaled quality score assigned by the variant caller) and PASSed all of the Filters.

IC-50 Analysis of Cisplatin Titration Curve Measuring Cell Viability
--------------------------------------------------------------------

H and J cybrids were plated in 96-well plates (10,000 cells/well), incubated for 24 h, and then treated with 0, 20, 40, 60, 80, 100, or 120 μM of cisplatin. The cybrids were incubated for another 48 h before having their cell viabilities measured with MTT reagent (Cat. \# 30006, Biotium, CA) and absorbance measured with an ELx808 spectrophotometer (Biotek) at 570 nm with reference wavelength at 630 nm. The background absorbance was subtracted from the signal absorbance and values normalized to the untreated specimen of each cell line. Each treatment was analyzed with eight replicates. An IC-50 analysis was performed to determine the concentration of cisplatin required to inhibit the cell viability by 50% (GraphPad Prism Software, Inc., San Diego, CA).

Cell Viability Assay
--------------------

H and J cybrids were plated in six-well plates (500,000 cells/well) and incubated for 24 h. Then cisplatin was added to media at concentrations of 0, 25, or 50 μM and incubated for another 48 h. Cells were counted using a Cell Viability Analyzer (ViCell, Beckman Coulter, Miami, FL) that incorporates a Trypan blue dye exclusion method. Cell numbers were normalized to H untreated and analyzed using the two-tailed *t*-test (GraphPad Prism). Experiments were analyzed in triplicate replicates and the entire experiment was repeated twice.

Mitochondrial Membrane Potential (ΔΨm) Assay
--------------------------------------------

H and J cybrids were plated in 24-well plates (100,000 cells/well) were incubated for 24 h and treated with 0 or 40 μM of cisplatin for another 48 h. JC-1 reagent (5,5′,6,6′-tetrachloro-1,1′,3,3′- tetraethylbenzimidazolylcarbocyanine iodide) (Biotium, Hayward, CA) was added to cultures for 15 min. Fluorescence was measured using a Gemini XPS Microplate Reader (Molecular Devices) for red (excitation 550 nm and emission 600 nm) and green (excitation 485 nm and emission 545 mm) wavelengths. Intact mitochondria with normal ΔΨm appeared red, while cells with decreased ΔΨm were in a green fluorescent state. Experiments were analyzed in quadruplicate and the entire experiment was repeated three separate times. Cisplatin-treated values were compared to untreated values for statistical significance (*P* ≤ 0.05, GraphPad Prism Software, Inc.).

Reactive Oxygen/Nitrogen Species (ROS) Assay
--------------------------------------------

H and J cybrids were plated in 24-well plates (100,000 cells/well) and incubated for 24 h. Cells were treated with 0 or 40 μM of cisplatin for another 24 or 48 h. ROS levels were measured with fluorescent dye 2,7-dichlorodihydrofluorescin diacetate (H~2~DCFDA, Invitrogen-Molecular Probes, Carlsbad, CA) on a fluorescence plate reader using 490 nm for emission and 520 nm for excitation wavelengths (Gemini XPS Microplate Reader, Molecular Devices, Sunnyvale, CA).

Our previous studies have shown that the J cybrids grow more rapidly than H cybrids ([@B17]) so the ROS levels were normalized per cell number. Simultaneously to the ROS experiments, H and J cybrids were plated in 6 well-plates (500,000 cells/plate), incubated 24 or 48 h, and treated in the identical fashion as described above. Cell viabilities were assessed by the Beckman Coulter ViCell Counter, allowing us to determine ROS levels per cell numbers. Differences in cisplatin-treated cells compared to untreated cells were analyzed (Prism, GraphPad Software Inc.) and were considered to be statistically significant when *P* ≤ 0.05. Experiments were analyzed in quadruplicate replicates and the entire experiment repeated three separate times.

RNA Isolation, cDNA Synthesis, and Quantitative Reverse Transcription PCR (qRT-PCR)
-----------------------------------------------------------------------------------

H and J cells were plated (500,000 cells/well) and incubated for 24 h in six-well plates. Cells were treated with culture media containing either 0 or 40 μM of cisplatin for another 48 h. Trypsinized cells were pelleted and RNA isolated following the manufacturer\'s protocol (RNeasy Kit, Qiagen, Valencia, CA). After RNA quantification (Nanodrop 1000, Thermoscientific, Wilmington, DE), the cDNA was transcribed from 100 ng of RNA (Qiagen), and then used for quantitative reverse transcription-PCR (qRT-PCR) (StepOnePlus instrument; Applied Biosystems, Carlsbad, CA). SYBR Green-based primers were used (Qiagen). [Table 2A](#T4){ref-type="table"} shows the GenBank Accession numbers and functions for 23 genes that were investigated. Cancer-related genes were Type 1 Cell-Surface Receptor for TGF-beta ligand superfamily (*ALK1*), Cytochrome P450, DNA Repair associated (*BRCA1*), Family 51, Subfamily A, Polypeptide 1 (*CYP51A*), Dehydrogenase/Reductase Member 2 (*DHRS2/HEP27*), Epidermal Growth Factor Receptor (*EGFR*), Erb-b2 Receptor Tyrosine Kinase 2 (*ERBB2*), Excision Repair Cross-Complementation Group 1 (*ERCC1*), and Secreted frizzled-related protein 1 (*SFRP1*). We also examined genes involved in cisplatin-induced nephrotoxicity and resistance ([@B26], [@B27]): ATP-Binding Cassette, Sub-Family C (*ABCC*1), Eukemia viral BMI-1 oncogene (*BMI1*), Cyclin-dependent kinase 2 (*CDK2*), Cyclin-dependent kinase inhibitor 1A (*CDKN1A*/*P21*), Lysine acetyltransferase 5 (*KAT5/TIP60*), and Tumor protein p53 (*TP53*).

Apoptosis genes were BCL2-associated X protein (*BAX*), BCL2 Binding Component 3 (*BBC3*), BCL2-Like-13 (*BCL2L13*), Caspase-3 (*CASP3*), and Caspase-9 (*CASP9*). Signaling genes include EGF-Containing Fibulin-Like Extracellular Matrix Protein-1 (*EFEMP1*), Mitogen-activated protein kinase 8 (*MAPK8*), Mitogen-activated protein kinase 10 (*MAPK10*), and Forkhead Box M1 (*FOXM1*). Target cycle thresholds (Ct) values were initially compared to the Ct values of reference genes and subsequently, comparisons between untreated and cisplatin-treated values (ΔΔCt) were evaluated for statistical significance. Fold differences were calculated using the equation 2^(ΔΔ*Ct*)^.

Statistical Analyses
--------------------

Statistical analysis of the data was performed by ANOVA (GraphPad Prism, version 5.0). Newman-Keuls multiple-comparison or the two-tailed *t*-tests were used to compare the data within each experiment. *P* ≤ 0.05 was considered statistically significant. Error bars in the graphs represent standard error of the mean (SEM).

Results {#s3}
=======

Sequencing of mtDNA From H and J Cybrids
----------------------------------------

The entire mtDNA from the J and H cybrids were sequenced using NGS technology. [Figure 1A](#F1){ref-type="fig"} shows the age and gender of person in this study. The private SNPs are those that do not define the J or H haplogroups (non-haplogroup defining). The unique SNPs are not listed in [www.MitoMap.org](http://www.MitoMap.org) or other programs. [Table 1A](#T1){ref-type="table"} shows the SNPs in the J haplogroup cybrids. There were 11 private SNPS in the mtDNA regions of the J cybrids: *C*YB 10-01 with m.2305T\>C (unique, no rs\#, MT-RNR2, unique) and m.10654C\>T (no rs\#, MT-ND4L, Ala62Val); CYB 10-05 with m.7226G\>A (rs369835151, MT-CO1, Syn:Ser441); m.13143 (rs386829174, MT-ND5, Syn:Asn269); and with m.16209T\>C (rs386829278, MT-CR, NonCoding); CYB 11-32 with m.6734G\>A (rs41413745, MT-CO1, Syn:Met332); CYB 13-43 with m.3847T\>C (no rs\#, MT-ND1, Syn:Leu181); m7805G\>A (no rs\#, MT-CO2, Val74Ile) and m.14208A\>G (no rs\#, MT-ND6, Thr156Ala); m.16263T\>A (rs386829294, CR;HV1, NonCoding); CYB 13-62 with m.6899GA (no rs\#, MT-CO1, Syn:Met332); and CYB 13-107 with m.8200T\>C (no rs\#, MT-CO2, Syn:Ser205) ([Table 1A](#T1){ref-type="table"}). The non-coding Control Region (CR) of the J cybrids possessed 17 SNPs and 10 of those defined the J haplogroup. The NGS methodology allowed identification of heteroplasmic SNPs in the J cybrids. The 13 heteroplasmy SNPs showed a range from 3.1 to 17.29% occurrence in five of the seven cybrids. CYB 10-05 and CYB 13-74 lacked heteroplasmy in the mtDNA.

###### 

SNPs found by NGS in J Haplogroup Cybrids.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Loci: MT-**   **SNP**      **AA Change**        **Locus**   **rs\#**      **CY 10-01**   **CY 10-05**   **CY 11-32**   **CY 12-43**   **CY 13-62**   **CY 13-74**   **CY 13-107**
  --------------- ------------ -------------------- ----------- ------------- -------------- -------------- -------------- -------------- -------------- -------------- ---------------
  CR:HV2/OHR      152 T\>C                          NonCoding   rs117135796   J1d                                                                                       

  CR:HV2/OHR      185 G\>A                          NonCoding   na                           J1c            J1c                                                         

  CR:HV2/OHR      200 A\>G                          NonCoding   rs372099630                                                                                             8.28%\
                                                                                                                                                                        Htroplsmy

  CR:HV2/OHR      228 G\>A                          NonCoding   rs41323649                   J1c            J1c                                          J1c            

  CR:HV2/OHR      242 C\>T                          NonCoding   na                                                                        J1b1a                         

  CR:HV2/OHR      271 C\>T                          NonCoding   na                                                         J1b1b                                        

  CR:HV2/OHR      295 C\>T                          NonCoding   rs41528348    J              J              J              J              J              J              J

  CR:HV3          462 C\>T                          NonCoding   rs41402146    J1             J1             J1             J1             J1             J1             J1

  CR:HV3          482 T\>C                          NonCoding   rs386419941                  J1c1                                                        J1c1           

  CR:HV3          489 T\>C                          NonCoding   rs28625645    J              J              J              J              J              J              J

  tRNA Phe        596 T\>C                          tRNA        na                                                                                                      5.4%\
                                                                                                                                                                        Htroplsmy

  RNR1            1007 G\>A                         rRNA        rs111033213   J1d1a                                                                                     

  RNR2            2158 T\>C                         rRNA        rs41349444                                                                J1b1a                         

  RNR2            2305 T\>C    Unique                           na            PVT-b                                                                                     

  RNR2:Hum        2655 G\>A    Unique                           na                                                         7.95%\                                       
                                                                                                                           Htroplsmy                                    

  RNR2            3010 G\>A                         rRNA        rs3928306     J1             J1             J1             J1             J1             J1             J1

  RNR2            3197 T\>C                         rRNA        rs2854131                                                                                               6.79%\
                                                                                                                                                                        Htroplsmy

  TER/TL1         3242 G\>A                         tRNA        rs193303018                                                                                             17.29%\
                                                                                                                                                                        Htroplsmy

  ND1             3394 T\>C    Tyr30His                         rs41460449                   J1c1                                                        J1c1           

  ND1             3847 T\>C    Syn:Leu181                       na                                                         PVT-a                                        

  ND1             4216 T\>C    Tyr304His                        rs1599988     JT             JT             JT             JT             JT             JT             JT

  ND2             5460 G\>A    Ala331Thr                        rs3021088                                                  J1b1           J1b1                          

  tRNA Cys        5821 G\>A                         tRNA        rs200587831   3.44%\                                                                                    
                                                                              Htroplsmy                                                                                 

  CO1             6261 G\>A    Ala120Thr                        rs201262114                  PVT-a                                                                      

  CO1             6554 C\>T    Syn:Thr217                       na                                          J1c7                                                        

  CO1             6734 G\>A    Syn:Met277                       rs41413745                                  PVT-b                                                       

  CO1             6899 G\>A    Syn:Met332                       na                                                                        PVT-b                         

  CO1             7146 A\>G    Thr415Ala                        rs372136420   3.25%\                                                                                    
                                                                              Htroplsmy                                                                                 

  CO1             7226 G\>A    Syn:Ser441                       rs369835151                  PVT-b                                                                      

  CO1             7256 C\>T    Syn:Asn451                       rs41542322    4.2%\                                        3.1%\                                        
                                                                              Htroplsmy                                    Htroplsmy                                    

  CO2             7747 C\>T    Syn:Asn54                        rs28608702                   J1b1b1c                                                                    

  CO2             7789 G\>A    Syn:Leu68                        rs386829014   J1d                                                                                       

  CO2             7805 G\>A    Val74Ile                         na                                                         PVT-b                                        

  CO2             7963 A\>G    Syn:Leu126                       na            J1d                                                                                       

  CO2             8192 A\>G    Asn203Tyr                        na                                                                                                      3.24%\
                                                                                                                                                                        Htroplsmy

  CO2             8200 T\>C    Syn:Ser205                       na                                                                                                      PVT-b

  CO2             8269 G\>A    Syn:Ter228                       na                                                         J1b            J1b                           J1b

  ATP8/ATP6       8557 G\>A    Syn:Leu64/Ala11Thr               rs386829040                                                               J1b1a                         

  CO3             9635 A\>C    Syn:Ser143                       na                                                                                       J1c1a          

  ND3             10398 A\>C   Thr114Ala                        rs2853826     J              J              J              J              J              J              J

  tRNA Arg        10410 T\>A                        tRNA        rs200478835                                                J1b1b1                                       

  ND4L            10654 C\>T   Ala62Val                         na            PVT-b                                                                                     

  ND4             11251 A\>G   Syn:Leu164                       rs3915952     JT             JT             JT             JT             JT             JT             JT

  ND4             11623 C\>T   Syn:Tyr288                       na                                                                                       J1c1a          

  ND4             11827 T\>C   Syn:Ala356                       rs368026942                                                               10.16%\                       
                                                                                                                                          Htroplsmy                     

  ND4             12007 G\>A   Syn:Trp416                       rs2853497                                                                 J1b1a                         

  ND4             12127 G\>A   Syn:Gly456                       na                                          J1c7                                                        

  ND5             12612 A\>G   Syn:Val92                        rs28359172    J              J              J              J              J              J              J

  ND5             13143 T\>C   Syn:Asn269                       rs386829174                  PVT-b                                                                      

  ND5             13708 G\>A   Ala458Thr                        rs28359178    J              J              J              J              J              J              J

  ND5             13879 T\>C   Ser515Pro                        rs200380057                                                J1b1           J1b1                          

  ND5             13899 T\>C   Syn:Tyr521                       rs370031192                                                                              J1c1a          

  ND6             14028 A\>G   Syn:Lys564                       na                                                         PVT-b                                        

  CYB             14798 T\>C   Phe18Leu                         rs28357681                   J1c            J1c                                          J1c            

  CYB             15452 C\>A   Leu236Ile                        rs527236209   JT             JT             JT             JT             JT             JT             JT

  CYB             15769 A\>G   Syn:Gln341                       na                                          4.9%\                                                       
                                                                                                            Htroplsmy                                                   

  CR:HV1          16069 C\>T                        NonCoding   rs147903261   J              J              J              J              J              J              J

  CR:TAS2         16092 T\>C                        NonCoding   na                                          J1c7                                                        

  CR:TAS2         16126 T\>C                        NonCoding   rs147029798   JT             JT             JT             JT             JT             JT             JT

  CR:7SDNA        16145 G\>A                        NonCoding   rs41419246                                                 J1b            J1b                           J1b

  CR:HV1          16193 C\>T                        NonCoding   na            J1d                                                                                       

  CR:HV1          16209 T\>C                        NonCoding   rs386829278                  PVT-b                                                                      

  CR:HV1          16222 C\>T                        NonCoding   rs386829282                                                J1b                                          

  CR:HV1          16261 C\>T                        NonCoding   rs138126107                                                J1b            J1b                           J1b

  CR:HV1          16263 T\>A                        NonCoding   rs386829294                                 J1c7           PVT-a                                        

  CR:HV1          16292 C\>T                        NonCoding   rs144417390                                                               PVT-a                         

  CR:HV1          16300 A\>G                        NonCoding   na            J1d1                                                                                      

  CR:HV1          16309 A\>G                        NonCoding   rs373517769   J1d1a                                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*PVT-a, found in other J or H haplogroups*.

*PVT-b, not found in other J or H haplogroups*.

*na:, not available*.

*All SNP\'s had a Quality (A Phred-scaled quality score assigned by the variant caller) Score of 100 and PASSed all the Filters*.

[Table 1B](#T2){ref-type="table"} shows the SNPs in the H haplogroup cybrids. There were 12 private SNPS in the mtDNA regions of the H cybrids: CYB 10-03 with m.1198A\>G (no rs\#, MT-RNR1), m.1477T\>C, (no rs\#, MT-RNR1) m.4483C\>G (unique, no rs\#, MT-ND2), m.9305G\>A, (no rs%, MT-CO3, Syn:Met33), m.9771T\>C, (unique, no rs\#, MT-CO3, Ser189Pro); m.16093T\>C (rs2853511, CR:TAS2, NonCoding); CYB 11-23, with m.1750G\>A, (rs28491689, MT-RNR2); m.3010G\>A (rs3928306, MT-RNR2); m.11587C\>T, (no rs\#, MT-ND4, Syn:Cys276); CYB 11-35 with m.3010G\>A, (rs3928306, MT-RNR2); and CYB 13-49 with m.13911A\>G, (no rs\#, MT-ND5, Syn:Met525); and m.14025T\>C (no rs\#, MT-ND5, Syn:Pro563). There were 8 SNPs in the non-coding Control Region with seven of those defining the H haplogroup. Four of the cybrids (CYB 10-07, CYB 11-10, CYB 11-23, and CYB 13-49) possessed heteroplasmy that ranged from 4.39 to 14.22%. The SNP variants associated with human diseases are listed in [Table 1C](#T3){ref-type="table"}. The m.3010G\>A variant (found in all seven of the J haplogroup cybrids and three of the H haplogroup cybrids) is associated with cyclic vomiting syndrome and migraines. The other SNP variants listed are found in either the J cybrids or the H cybrids but not both.

###### 

SNPs found by NGS in H Haplogroup Cybrids.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Loci: MT-**   **SNP**      **AA Change**   **Locus**   **rs\#**      **CY 10-03**   **CY 10-04**   **CY 10-07**   **CY 11-10**   **CY 11-23**   **CY 11-35**   **CY 13-49**
  --------------- ------------ --------------- ----------- ------------- -------------- -------------- -------------- -------------- -------------- -------------- --------------
  CR:HV2          73 G\>A                      NonCoding   rs3087742     H              H              H              H              H              H              H

  CR:HV2/\        195 T\>C                     NonCoding   rs2857291                                                  H4a1a+195                                    
  OHR                                                                                                                                                              

  CR:HV3          456 C\>T                     NonCoding   rs41356551                   H5\'36                                                                     

  RNR1            750 A\>G                     rRNA        rs2853518     H2a                           H2a                                                         

  RNR1            961 T\>G                     rRNA        rs3888511                                                                 H11a                          

  RNR1            1198 A\>G                    rRNA        na            PVT-b                                                                                     

  RNR1            1438 A\>G                    rRNA        rs2001030     H                             H                                                           

  RNR1            1477 T\>C                    rRNA        na            PVT-b                                                                                     

  tRNA Val        1630 A\>C                    tRNA        na                           H5                                                                         

  RNR2            1750 G\>A                    rRNA        rs28491689                                                                PVT-b                         

  RNR2            2159 T\>C                    rRNA        na            H63                                                                                       

  RNR2            2706 A\>G                    rRNA        rs2854128     H              H              H              H              H              H              H

  RNR2            3010 G\>A                    rRNA        rs3928306                                                                 PVT-b          PVT-a          PVT-a

  ND1             3926 T\>C    Leu207Pro                   na                                                                                                      14.22%\
                                                                                                                                                                   Htroplsmy

  ND1             3992 C\>T    Thr229Met                   rs41402945                                                 H4                                           

  ND1             4024 A\>G    Thr240Ala                   rs41504646                                                 H4a                                          

  tRNA Gln        4336 T\>C                    tRNA        rs193303033                  H5a                                                                        

  ND2             4483 C\>G    Ala5Gly                     na            PVT-b                                                                                     

  ND2             4733 T\>C    Syn:Asn88                   na                                                                                                      PVT-a

  ND2             4769 A\>G    Syn:Met100                  rs3021086     H2                                                                                        

  ND2             4896 T\>C    Tyr143His                   na                                                         4.39%\                                       
                                                                                                                      Htroplsmy                                    

  ND2             5004 T\>C    Syn:Leu179                  rs41419549                                                 H4a                                          

  ND2             5051 A\>G    Syn:Leu194                  na                           H5a1i                                                                      

  ND2             5301 A\>G    Ile278Val                   rs199794187                                                                                             

  NC3             5585 G\>A                    NonCoding   rs386828973                                                               H11a2a2                       

  CO1             6303 G\>A    Gly134Stop                  na                                                                                                      5.41%\
                                                                                                                                                                   Htroplsmy

  CO1             6505 T\>C    Val201Ala                   rs28371932                                                                                              12.21%\
                                                                                                                                                                   Htroplsmy

  CO1             6951 G\>A    Val350Met                   na                                                         PVT-a                                        

  CO1             7028 T\>C    Syn:Ala375                  rs2015062     H              H              H              H              H              H              H

  CO1             7337 G\>A    Syn:Ser478                  rs386829005                                 H66                                                         

  CO2             8269 G\>A    Syn:Term228                 rs8896                                                     H4a1a                                        

  tRNA Lys        8343 A\>G                    tRNA        na                                          PVT-a                                                       

  ATP8            8448 T\>C    Met28Thr                    na                                                                        H11                           

  ATP8            8512 A\>G    Syn:Lys49                   na                                                                                                      

  ATP6            9123 G\>A    Syn:Leu199                  rs28358270                                                 H4                                           

  CO3             9305 G\>A    Syn:Met33                   na            PVT-b                                                                                     

  CO3             9771 T\>C    Ser189Pro                   na            PVT-b                                                                                     

  CO3             9777 G\>A    Gly191Ser                   na                                          13.99%\                                                     
                                                                                                       Htroplsmy                                                   

  ND4L            10750 A\>G   Asn94Ser                    rs372297272                                                5.88%\                                       
                                                                                                                      Htroplsmy                                    

  ND4             11587 C\>T   Syn:Cys276                  na                                                                        PVT-b                         

  ND4             11719 G\>A   Syn:Gly320                  rs2853495     H              H              H              H              H              H              H

  ND4             12130 T\>C   Syn:Phe457                  na                                                                        9.53%\                        
                                                                                                                                     Htroplsmy                     

  ND5             13759 G\>A   Ala475Thr                   rs386420019                                                               H11                           

  ND5             13889 G\>A   Cys518Tyr                   na                                                         H4a1a3                                       

  ND5             13911 A\>G   Syn:Met525                  na                                                                                                      PVT-b

  ND5             14025 T\>C   Syn:Pro563                  na                                                                                                      PVT-a

  ND6             14365 C\>T   Syn:Met73                   rs2853815                                                  H4a1                                         

  ND6             14582 A\>G   Val31Ala                    rs41354845                                                 8.61%\                                       
                                                                                                                      Htroplsmy                                    

  ND6             14587 A\>G   Asp147Ala                   na                                                                        H11a2                         

  CYB             14861 G\>A   Ala39Thr                    rs2853505                                                  4.96%\                                       
                                                                                                                      Htroplsmy                                    

  CYB             15670 T\>C   Syn:His308                  rs527236211                                                               H11a2a2                       

  CYB             15833 C\>T   Syn:Leu363                  rs41504845                   H5a1                                                                       

  CR:TAS2         16092 T\>C                   NonCoding   na                                                                        H11a2                         

  CR:TAS2         16093 T\>C                   NonCoding   rs2853511     PVT-a                                                                                     

  CR:7SDNA        16140 T\>C                   NonCoding   rs3134562                                                                 H11a2a                        

  CR:7SDNA        16153 G\>A                   NonCoding   rs2853512                    H5a1i                                                                      

  CR:7SDNA        16265 A\>G                   NonCoding   rs386829295                                                               H11a2a2                       

  CR:HV1          16293 A\>G                   NonCoding   rs386828867                                                               H11a                          

  CR:HV1          16304 T\>C                   NonCoding   rs386829305                  H5                                                                         

  CR:HV1          16311 T\>C                   NonCoding   rs34799580                                                                H11                           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*PVT-a, found in other J or H haplogroups*.

*PVT-b, not found in other J or H haplogroups*.

*na, not available*.

*All SNP\'s had a Quality (A Phred-scaled quality score assigned by the variant caller) Score of 100 and PASSed all the Filters*.

###### 

Diseases associated with SNPs[^\*^](#TN1){ref-type="table-fn"} Identified in the J and H Cybrids.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Loci: MT-**   **SNP**      **AA Change**   **Locus**   **Cybrids with SNP**   **Disease**
  --------------- ------------ --------------- ----------- ---------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  RNR1            961 T\>G                     rRNA        H 1/7                  Possible DEAF Associated

  RNR2            3010 G\>A                    rRNA        J 7/7\                 Cyclic Vomiting Syndrome with Migraine
                                                           H 3/7                  

  TER/TL1         3242 G\>A                    tRNA        J 1/7                  Mitochondrial Myopathy/Maternally inherited Hypertrophic Cardiomyopathy/ Renal Tubular Dysfunction; Myelodysplastic syndrome

  ND1             3394 T\>C    Tyr30His                    J 2/7                  Leber Hereditary Optic Neuropathy/Carnitine PalmitoylTranserase Deficiency/High Altitude Adaptation

  ND1             4216 T\>C    Tyr304His                   J 7/7                  Leber Hereditary Optic Neuropathy/Insulin Resistance/Possible Adaptive High Altitude Variance

  tRNA Q          4336 T\>C                    tRNA        H 1/7                  Alzheimer\'s Disease/Parkinson\'s Disease/ Hearing Loss & Migraine/Autism Spectrum/Intellectual Disability

  ND2             5460 G\>A    Ala331Thr                   J 2/7                  Alzheimer\'s Disease/Parkinson\'s Disease

  tRNA C          5821 G\>A                    tRNA        J '1/7                 Deaf Helper Mutation/Maternally inherited DEAFness/Aminoglycoside-induced DEAFness

  COI             6261 G\>A    Ala120Thr                   J 1/7                  Prostate Cancer/Leber Hereditary Optic Neuropathy

  tRNA K          8343 A\>G                    tRNA        H 1/7                  Possible Parkinson\'s Disease Risk Factor

  ND3             10398 A\>C   Thr114Ala                   J 7/7                  Parkinson\'s Disease Protective Factor/Longevity/Altered Cell pH/Metabolic Syndrome/Breast Cancer Risk/Attention Deficit Hyperactivity Disorder/Cognitive Decline/SpinoCerebellar Ataxia Type 2 Age Onset

  ND5             13708 G\>A   Ala458Thr                   J 7/7                  Leber Hereditary Optic Neuropathy/Increased Multiple Sclerosis Risk/Higher Frequency in Parkinson\'s Disease/Alzheimer\'s Disease

  ND6             14582 A\>G   Val31Ala                    H 1/7                  Leber Hereditary Optic Neuropathy Synergistic 14258A + 14582G

  CR:TAS2         16093 T\>C                   NonCoding   H 1/7                  Cyclic Vomiting Syndrome

  CR:HV1          16300 A\>G                   NonCoding   J 1/7                  Bipolar Disorder Associated
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Information obtained from [www.MitoMap.org](http://www.MitoMap.org) and [www.HmtVar.uniba.it](http://www.HmtVar.uniba.it)*.

IC50 Analyses Results
---------------------

IC-50 analyses were performed to determine the concentration of cisplatin required to inhibit the cell viability by 50% ([Figure 2](#F2){ref-type="fig"}). The Goodness of Fit values were *R*^2^ = 0.8388 and *R*^2^ = 0.8828 for the H and J cybrids, respectively. The IC-50 values for cybrid-H were 47.13 μM (95% confidence interval 38.62--57.53 μM) and for cybrid-J were 41.06 μM (95% confidence interval 29.49 and 57.18 μM).

![The IC-50 values for the J cybrids were lower (41.06 μM) compared to the H cybrids (47.13 μM). H and J cybrids were plated in 96-well plates, treated with 0, 20, 40, 60, 80, 100, or 120 μM of cisplatin and the cell viabilities measured with MTT reagent. The Goodness of Fit values for the H cybrids were *R*^2^ = 0.8388 and 95% confidence interval 38.62--57.53 μM. The J cybrid Goodness of Fit values were *R*^2^ = 0.8828 and 95% confidence interval 29.49--57.18 μM. Each treatment was analyzed with eight replicates.](fonc-09-00640-g0002){#F2}

Viability of H and J Cybrids After Cisplatin Treatment
------------------------------------------------------

The H and J cybrids were treated for 48 h with either 0, 25, or 50 μM cisplatin and cell viabilities measured using a Trypan Blue dye exclusion assay. The cell viability for the untreated J cybrid (Cyb J Unt) was normalized to the untreated H cybrids (Cyb H Unt, 100.0% ± 16.3). Without treatment, the J cybrids grew at a faster rate than H cybrids (226.5% ± 30.7 vs. 100.0% ± 16.3, *P* = 0.001, [Figure 3A](#F3){ref-type="fig"}). Cell viability of H cybrids decreased 13% (*P* = 0.58) after 25 μM cisplatin treatment and to 38% (*P* = 0.05) after 50 μM cisplatin treatment compared to untreated-H cybrids (100.0% ± 16.3). Compared to untreated-J cybrids, viability decreased 35% (*P* = 0.04) and 65% (*P* = 0.002) for the 25 and 50 μM cisplatin-treated-J cybrids, respectively. Thus, cell viabilities of J cybrids were more sensitive to cisplatin treatment than those of H cybrids.

![**(A)** The J cybrids were more sensitive to cisplatin treatment than the H cybrid cultures. Cell viabilities of the untreated and cisplatin-treated cybrids were measured using the trypan blue dye exclusion assay and normalized to the untreated-H cybrid sample (Cyb H Unt, 100.0 ± 16.3). The viability in untreated-J cybrids increased at 2.26-fold higher rate than the untreated-H cybrids (*P* = 0.001). The viability declined in the 25 μM cisplatin-treated-H cybrids (13%, *P* = 0.58) and 50 μM cisplatin-treated-H cybrids (38%, *P* = 0.05) compared to the untreated-H cybrids. The viability decreased in the 25 μM cisplatin-treated-J cybrids (35%, *P* = 0.05) and 50 μM cisplatin-treated-J cybrids (65%, *P* = 0.002) compared to the untreated-J cybrids. Each experiment was repeated twice and analyzed in triplicate. **(B)** J cybrids have a greater loss of mitochondrial membrane potential (ΔΨm) after cisplatin treatment than H cybrids. The ΔΨm values in cisplatin-treated-J cybrids were significantly decreased compared to the untreated-J cybrids (*P* = 0.0001) and also the cisplatin-treated H cybrids (*P* = 0.0005). In contrast, the cisplatin-treated and untreated-H cybrids showed similar levels to each other (*P* = 0.51). ΔΨm, mitochondria membrane potential; RFU, relative fluorescent units. ^\*^*P* \< 0.05; ^\*\*^*P* \< 0.01; ^\*\*\*^*P* \< 0.001. **(C)** Cisplatin-treated-H cybrids produced higher levels of ROS compared to the cisplatin-treated-J cybrids. The ROS levels, as measured in relative percentile, were compared between the H and J cybrids without and with cisplatin treatments after 48 h. The cisplatin-treated-J cybrids had significantly lower ROS levels compared to the untreated-J cybrids (*P* = 0.03) and also compared to the cisplatin-treated-H cybrids (*P* = 0.006). The ROS levels for the untreated H and cisplatin-treated H were similar to each other (*P* = 0.37). RFU = relative fluorescent units. ^\*^*P* \< 0.05.](fonc-09-00640-g0003){#F3}

Mitochondrial Membrane Potential (ΔΨm) After Cisplatin Treatment
----------------------------------------------------------------

The effects of cisplatin on the ΔΨm of H and J cybrids were analyzed after 48 h incubation ([Figure 3B](#F3){ref-type="fig"}). The cisplatin-treated-H cybrids showed similar ΔΨm compared to the untreated-H cybrids (105.3% ± 7.45 vs. 100.0% ± 2.6, *P* = 0.51, respectively). The cisplatin-treated-J cybrids showed a significant reduction of ΔΨm compared to the untreated-J cybrids (75.9% ± 3.6 vs. 100.0% ± 2.0, *P* = 0.0001, respectively). In addition, cisplatin-treated-J cybrids showed a 29.4% decrease in Relative Fluorescent Units (RFU) compared to cisplatin-treated-H cybrids (75.9% ± 3.6 vs. 105.3% ± 7.5, *P* = 0.0005). These findings indicate that J cybrids have a greater loss of ΔΨm after cisplatin treatment than H cybrids.

Reactive Oxygen Species (ROS) Production After Cisplatin Treatment
------------------------------------------------------------------

The ROS levels, measured in RFU, were compared between the H and J cybrids with and without cisplatin treatments after 48 h incubation ([Figure 3C](#F3){ref-type="fig"}). The cisplatin-treated-J cybrids showed significantly lower ROS compared to the untreated-J cybrids (56.79% ± 7.731 vs. 78.33% ± 4.24, *P* = 0.03, respectively) and also compared to cisplatin-treated-H cybrids (98.26% ± 8.66, *P* = 0.03). There was no difference between the cisplatin-treated-H cybrids and untreated-H cybrids after 48 h incubation (*P* = 0.37). Since ROS production levels had been normalized to cell viability for each condition, our findings showed that after cisplatin treatment, the J cybrid cultures showed significantly less ROS production compared to H treated cybrid cultures.

Gene Expression Levels in H and J Cybrids Treated With Cisplatin
----------------------------------------------------------------

### Cancer-Related Pathway Genes

The *CYP51A* gene expression levels were similar in untreated-H and untreated-J cybrids (1.14 ± 0.14-fold, *P* = 0.63, [Table 2B](#T5){ref-type="table"}). However, after cisplatin treatment, the J-treated cybrids showed increased transcription levels compared to untreated-J cybrids (1.94 ± 0.12-fold, *P* = 0.0057) while the cisplatin-treated-H cybrids were similar to untreated-H cybrids (*P* = 0.12).

###### 

Description of genes analyzed in cisplatin treated H and J cybrids.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Symbol**     **Gene name**                                                  **Genbank accession numbers**   **Functions**
  -------------- -------------------------------------------------------------- ------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                **CANCER-RELATED**

  *ABCC1*        ATP-Binding Cassette,\                                         [NM_004996](NM_004996)          Known as MRP1 (multidrug resistance protein 1). Member of the ATP binding cassette family that transports molecules across membranes. Mutations in ABCC1 N-glycosylation connected with Cisplatin resistance.
                 SubFamily C                                                                                    

  *ALK1*         Type 1 Cell-Surface Receptor for TGF-beta ligand superfamily   [NM_000020](NM_000020)          Type Cell-Surface receptor for TGF-beta superfamily of ligands. Shares similar domain structures in serine-threonine kinase subdomains with other activing receptor-like kinase proteins.

  *BRCA1*        DNA Repair associated                                          [NM_007294](NM_007294)          Nuclear Phosphoprotein that acts as a tumor suppressor by maintaining genomic stability. Involved in transcription, DNA repair of double-stranded breaks, and recombination.

  *BMI1*         Eukemia viral BMI-1 oncogene                                   [NM_005180](NM_005180)          Stem cell marker. Has key role in regulating the proliferative activity of both normal and leukemic stem cells.

  *CDK2*         Cyclin dependent kinase 2                                      [NM_001798](NM_001798)          Associated with apoptosis. Essential for completion of prophase I during meiotic cell division in male and female germ cells.

  *CDKN1A/P21*   Cyclin-dependent kinase inhibitor 1A/ p21                      [NM_000389](NM_000389)\         Plays a critical role in the cellular response to DNA damage and cisplatin toxicity. Mediates cell cycle arrest. Is cyto-protective.
                                                                                [NM_001220777](NM_001220777)\   
                                                                                [NM_001220778](NM_001220778)\   
                                                                                [NM_078467](NM_078467)\         
                                                                                [NM_001291549](NM_001291549)    

  *CYP51A*       Cytochrome P450, Family 51, Subfamily A, Polypeptide 1         [NM_000786](NM_000786)\         Member of the cytochrome P450 enzyme family of monooxygenases.
                                                                                [NM_001146152](NM_001146152)    

  *DHRS2/*\      Dehydrogenase/\                                                [NM_182908](NM_182908)\         NADPH-dependent dicarbonyl reductase activity. Mitochondrial matrix protein. Inhibits MDM2 and stabilizes p53.
  *HEP27*        Reductase (SDR Family) Member 2                                [NM_005794](NM_005794)          

  *EGFR*         Epidermal Growth Factor Receptor                               [NM_005228](NM_005228)          Triggers cell proliferation when bound to epidermal growth factor

  *ERBB2*        Erb-b2 Receptor Tyrosine Kinase 2                              [NM_004448](NM_004448)          Member of epidermal growth factor receptor family of receptor tyrosine kinases. Stabilizes binding of epidermal growth factor to receptor

  *ERCC1*        Excision Repair Cross-Complementation Group 1                  [NM_001166049](NM_001166049)\   Nucleotide Excision Repair formed by electrophilic compounds such as Cisplatin. Forms a heterodimer with XPF endonuclease. Involved in recombination DNA repair, inter-stand crosslink, and lesion repair.
                                                                                [NM_001983](NM_001983)\         
                                                                                [NM_202001](NM_202001)          

  *KAT5/*\       K (Lysine) acetyltransferase 5                                 [NM_001206833](NM_001206833)\   Drug resistance; has role in acetylation of histones; modulates DNA damage response.
  *TIP60*                                                                       [NM_006388](NM_006388)\         
                                                                                [NM_182709](NM_182709)\         
                                                                                [NM_182710](NM_182710)          

  *SFRP1*        Secreted frizzled-related protein 1                            [NM_003012](NM_003012)          Soluble modulators of Wnt signaling. Regulates cell growth and differentiation. Silencing leads to deregulated pathway, associated with cancer.

  *TP53*         Tumor protein p53                                              [NM_000546](NM_000546)\         Regulates genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Induces apoptosis.
                                                                                [NM_001126112](NM_001126112)\   
                                                                                [NM_001126113](NM_001126113)\   
                                                                                [NM_001126114](NM_001126114)\   
                                                                                [NM_001126115](NM_001126115)\   
                                                                                [NM_001126116](NM_001126116)\   
                                                                                [NM_001126117](NM_001126117)\   
                                                                                [NM_001126118](NM_001126118)\   
                                                                                [NM_001276695](NM_001276695)\   
                                                                                [NM_001276696](NM_001276696)\   
                                                                                [NM_001276697](NM_001276697)\   
                                                                                [NM_001276698](NM_001276698)\   
                                                                                [NM_001276699](NM_001276699)\   
                                                                                [NM_001276760](NM_001276760)\   
                                                                                [NM_001276761](NM_001276761)    

                                                                                                                **APOPTOSIS**

  *BAX*          BCL2-Associated X Protein                                      [NM_001291429](NM_001291429)\   Associates to form a heterodimer with BCL2. Functions in apoptotic behavior by opening the mitochondrial voltage dependent anion channel, leading to loss of membrane potential, and opening of cytochrome C.
                                                                                [NM_001291428](NM_001291428)\   
                                                                                [NM_001291430](NM_001291430)\   
                                                                                [NM_138761](NM_138761)\         
                                                                                [NM_004324](NM_004324)\         
                                                                                [NM_138764](NM_138764)\         
                                                                                [NM_001291431](NM_001291431)\   
                                                                                [NM_138763](NM_138763)          

  *BBC3*         BCL2 Binding Component 3                                       [NM_001127240](NM_001127240)\   Member of the BCL-2 family. Induces mitochondrial membrane permeablization and apoptosis.
                                                                                [NM_001127241](NM_001127241)\   
                                                                                [NM_014417](NM_014417)          

  *BCL2L13*      BCL2-Like-1                                                    [NM_015367](NM_015367)\         BCL2 isoform. Mitochondrial-localized protein. Overexpression results in apoptosis.
                                                                                [NM_001270729](NM_001270729)\   
                                                                                [NM_001270731](NM_001270731)\   
                                                                                [NM_001270732](NM_001270732)\   
                                                                                [NM_001270734](NM_001270734)\   
                                                                                [NM_001270735](NM_001270735)    

  *CASP3*        Caspase-3                                                      [NM_004346](NM_004346)\         Effector caspase; Activated by caspases 8, 9, and 10. Effects caspases 6, 7, 9. Belongs to family of proteases involved in apoptosis; Synthesized as inactive precursors and therefore need activation.
                                                                                [NM_032991](NM_032991)          

  *CASP9*        Caspase-9                                                      [NM_001229](NM_001229)\         Part of the apoptosome protein complex formed during apoptosis. Mitochondrial caspase activation.
                                                                                [NM_032996](NM_032996)          

                                                                                                                **SIGNALING**

  *EFEMP1*       EGF-Containing Fibulin-Like Extracellular Matrix Protein-1     [NM_001039349](NM_001039349)\   Fibulin family of extracellular matrix glycoproteins. Binds to epidermal growth factor receptors causing phosphorylation and signaling.\
                                                                                [NM_001039348](NM_001039348)    Associated with drug resistance and cancer prognosis.

  *FOXM1*        Forkhead Box M1                                                [NM_001243088](NM_001243088)\   Transcriptional activator involved in cell proliferation.\
                                                                                [NM_001243089](NM_001243089)\   Regulates expression of several cyclins.\
                                                                                [NM_021953](NM_021953)\         Role in DNA break repairs.\
                                                                                [NM_202002](NM_202002)\         Phosphorylated and inactivated during mitosis.
                                                                                [NM_202003](NM_202003)          

  *MAPK8*        Mitogen-activated protein kinase 8                             [NM_002750](NM_002750)\         Targets specific transcription factors. Mediates immediate-early gene expression. Involved in UV radiation induced apoptosis.
                                                                                [NM_139046](NM_139046)\         
                                                                                [NM_139047](NM_139047)\         
                                                                                [NM_139049](NM_139049)\         
                                                                                [NM_001278547](NM_001278547)\   
                                                                                [NM_001278548](NM_001278548)    

  *MAPK10*       Mitogen-activated protein kinase 10                            [NM_002753](NM_002753)\         Regulatory role in signaling pathways during neuronal apoptosis;\
                                                                                [NM_138980](NM_138980)\         Inhibited by cyclin dependent kinase 5.
                                                                                [NM_138982](NM_138982)          

                                                                                                                **HOUSEKEEPERS**

  *ALASV1*       5\'-amino-levulinate synthase 1                                [NM_000688](NM_000688)          Mitochondrial enzyme catalyzes rate-limiting step in heme biosynthesis. Level of the mature encoded protein regulated by heme.

  *GUSB*         Glucuronidase, beta                                            [NM_000181](NM_000181)\         Belongs to the glycosidase family of enzymes that break down complex carbohydrates.
                                                                                [NM_001284290](NM_001284290)\   
                                                                                [NM_001293104](NM_001293104)\   
                                                                                [NM_001293105](NM_001293105)    

  *HMBS*         Hydroxy-methylbilane synthase                                  [NM_000190](NM_000190)\         Third enzyme of heme biosynthetic pathway; Catalyzes condensation of four porphobilinogen molecules into hydroxymethylbilane.
                                                                                [NM_001024382](NM_001024382)\   
                                                                                [NM_001258208](NM_001258208)\   
                                                                                [NM_001258209](NM_001258209)    

  *HPRT1*        Hypoxanthine phosphor-ribosyl-transferase 1                    [NM_000194](NM_000194)          Transferase catalyzes conversion of hypoxanthine to inosine monophosphate and guanine to guanosine monophosphate.

  *TUBB*         Tubulin beta\                                                  [NM_178014](NM_178014)\         Part of protein superfamily of globular proteins. Major component of microtubules.
                 class I                                                        [NM_001293213](NM_001293213)    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Expression levels in cisplatin treated H and J cybrids.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Symbol**                 **Untreated**\                                      **H Cybrids Untreated[^**\#**^](#TN2){ref-type="table-fn"} vs Treated**\   **J Cybrids**\                                            **Treated**\
                             **Cybrids**\                                        ***P* value, Fold**                                                        **Untreated[^**\#**^](#TN2){ref-type="table-fn"} vs.**\   **Cybrids**\
                             **H[^**\#**^](#TN2){ref-type="table-fn"} vs. J**\                                                                              **Treated**\                                              **H[^**\#**^](#TN2){ref-type="table-fn"} vs. J**\
                             ***P* value, Fold**                                                                                                            ***P* value, Fold**                                       ***P* value, Fold**
  -------------------------- --------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------
  **CANCER-RELATED GENES**                                                                                                                                                                                            

  *ABCC1*                    0.35,\                                              0.24,\                                                                     0.21,\                                                    **0.02**,\
                             0.77 ± 0.19                                         0.82 ± 0.078                                                               0.63 ± 0.095                                              0.56 ± 0.084

  *CDKN1A/P21*               0.61,\                                              **0.002**,\                                                                0.12,\                                                    0.13 0.68 ± 0.14
                             1.41 ± 0.66                                         4.89 ± 0.51                                                                3.12 ± 0.65                                               

  *CYP51A*                   0.63,\                                              0.12,\                                                                     **0.0057**,\                                              0.75,\
                             1.14 ± 0.14                                         2.01 ± 0.47                                                                1.94 ± 0.12                                               1.14 ± 0.07

  *DHRS2/HEP27*              0.47,\                                              0.89,\                                                                     0.75,\                                                    **0.02**,\
                             0.79 ± 0.17                                         1.08 ± 0.14                                                                1.12 ± 0.42                                               0.53 ± 0.06

  **APOPTOSIS GENES**                                                                                                                                                                                                 

  *BAX*                      0.97,\                                              0.32,\                                                                     **0.05**,\                                                0.28,\
                             1.01 ± 0.09                                         1.32 ± 0.26                                                                1.78 ± 0.26                                               1.4 ± 0.21

  *CASP3*                    0.63,\                                              0.12,\                                                                     **0.02**,\                                                0.57,\
                             1.14 ± 0.14                                         2.01 ± 0.47                                                                3.33 ± 0.62                                               1.4 ±0.26

  **SIGNALING GENES**                                                                                                                                                                                                 

  *EFEMP1*                   0.57,\                                              0.14,\                                                                     0.34,\                                                    **0.04**,\
                             0.79 ± 0.32                                         0.69 ± 0.16                                                                0.43 ± 0.21                                               0.31 ± 0.08

  *SFRP1*                    0.49,\                                              0.28,\                                                                     **0.05**,\                                                0.19,\
                             0.97 ± 0.30                                         0.53 ± 0.26                                                                0.14 ± 0.04                                               0.77 ± 0.21
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Fold values \>1 indicate up-regulation of the gene*.

*Fold values \<1 indicate down-regulation of the gene*.

*are assigned a value of 1*.

*P values ≤ 0.05 are statistically significant and are bolded*.

Levels of *CDKN1A/p21* were similar in untreated-J and H cybrids (*P* = 0.61) but the cisplatin-treated-H cybrids showed significant upregulation compared to the untreated-H cybrid (4.89 ± 0.51-fold, *P* = 0.002; [Table 2B](#T5){ref-type="table"}). The *CDKN1A/p21* levels in cisplatin-treated-J cybrids trended higher, but were not significant (3.12-fold, *P* = 0.12). Gene expression levels of both *ABCC1* and *DHRS2/HEP27* in cisplatin-treated-J cybrids were significantly lower than that of cisplatin-treated-H cybrids (0.56 ± 0.084-fold, *P* = 0.02 and 0.53 ± 0.06-fold, *P* = 0.02, respectively). The cisplatin-treated-J cybrids had decreased *SFRP1* gene expression levels compared to untreated-J cybrids (0.14 ± 0.04-fold, *P* = 0.05). In contrast, the untreated-H and cisplatin-treated-H cybrids were *SFRP1* levels were similar to each other (*P* = 0.28). These findings demonstrate that expression levels of *ABCC1, CYP51A, CDKN1A/p21, DHRS2/HEP27*, and *SFRP1* genes are differentially influenced in cells containing H vs. J mtDNA profiles.

The levels of *ALK, BRCA1, BMI1, CDK2, EGFR, ERBB2, ERCC1, KAT5/TIP60*, and *TP53* were not different from each other in the H and J cybrids under any conditions (with or without cisplatin treatment; data not shown).

### Apoptosis Pathway Genes

Untreated-H and untreated-J cybrids expressed similar levels of *BAX* (1.01-fold, *P* = 0.97). After cisplatin exposure, *BAX*, and *CASP3* levels increased in cisplatin-treated-J cybrids compared to the untreated-J cybrids (1.78 ± 0.26-fold, *P* = 0.05 and 3.33 ± 0.62-fold, *P* = 0.02, respectively). In contrast, the treated and untreated-H cybrids were not significantly different from each other (*BAX, P* = 0.32 and *CASP3, P* = 0.12). The *BBC3, BCL2L13*, and *CASP9* gene levels were similar in H and J cybrids with or without cisplatin treatment, indicating that cisplatin did not affect these apoptotic genes. These findings indicate that in the J cybrids, cisplatin-induced apoptosis upregulation of *BAX* and *CASP3*.

### Signaling Pathway Genes

The cisplatin-treated-J cybrids demonstrated lower *EFEMP1* gene expression levels than cisplatin-treated-H cybrids (0.31 ± 0.08-fold, *P* = 0.04). The *MAPK8, MAPK10*, and *FOXM1* expression levels were not different between H and J cybrids, nor were they affected by cisplatin treatment (data not shown).

Target Sites for Cisplatin Within the MT-Dloop and Comparison of mtDNA GG Stretches
-----------------------------------------------------------------------------------

The entire control regions of H (*n* = 6) and J (*n* = 7) cybrids were sequenced ([Table 3](#T6){ref-type="table"}) and analyzed for the numbers of GG stretches, which are known to be target DNA sequences for cisplatin ([@B28]). The MT-Dloop was analyzed because it is the region controlling replication and transcription for mtDNA. In H cybrids (*n* = 6) and J cybrids (*n* = 7) there were three GGG stretches (nt16455-16457; nt16516-16518, and nt34-36), one GGGGG stretch (nt16470-16474), and one GGGGGG stretch (nt66-71) site. One H cybrid had a GGGG stretch (nt322-325) that was lacking in any of other H or J cybrids. Greatest variability was found in regions of GG stretches: nucleotides (nt) 184-185 (5/7 in J cybrids); nt228-229 (4/7 in J cybrids); nt322-323 (5/6 in H cybrids); nt513-514 (1/6 H cybrids); and nt526-527 (1/6 H cybrids). A difference in GG stretch patterns of H vs. J cybrids may potentially lead to variations in numbers of cisplatin-mtDNA adducts. However, we believe additional studies will be needed to clarify mechanisms of interaction between the mtDNA and cisplatin that might affect cellular responses.

###### 

Total numbers of GG stretches in the MT-Dloop (nt16441 to nt601) of H cybrids vs. J cybrids.

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  **mtDNA Haplogroup**   **Total nucleotides**   **GG**                 **GGG**                **GGGG**          **GGGGG**               **GGGGGG**
  ---------------------- ----------------------- ---------------------- ---------------------- ----------------- ----------------------- ---------------
  H                      760                     nt16503-16504 (6/6)\   nt16455-16457 (6/6)\   nt322-325 (1/6)   nt16470-16474 (6/6)     nt66-71 (6/6)
                                                 nt16569-01 (6/6)\      nt16516-16518 (6/6)\                                             
                                                 nt08-09 (6/6)\         nt34--36 (6/6)                                                   
                                                 nt53-54 (6/6)\                                                                          
                                                 nt100-101 (6/6)\                                                                        
                                                 nt106-107 (6/6)\                                                                        
                                                 nt184-185 (6/6)\                                                                        
                                                 nt228-229 (6/6)\                                                                        
                                                 nt322-323 (5/6)\                                                                        
                                                 nt409-410 (6/6)\                                                                        
                                                 nt412-413 (6/6)\                                                                        
                                                 nt513-514 (1/6)\                                                                        
                                                 nt526-527 (1/6)                                                                         

  J                      760                     nt16503-16504 (7/7)\   nt16455-16457 (7/7)\   0                 nt16470-nt16474 (7/7)   nt66-71 (6/6)
                                                 nt16569-01 (7/7)\      nt16516-16518 (7/7)\                                             
                                                 nt08-09 (7/7)\         nt34--36 (7/7)                                                   
                                                 nt53-54 (7/7)\                                                                          
                                                 nt100-101 (7/7)\                                                                        
                                                 nt106-107 (7/7)\                                                                        
                                                 nt184-185 (5/7)\                                                                        
                                                 nt228-229 (4/7)\                                                                        
                                                 nt322-323 (7/7)\                                                                        
                                                 nt409-410 (7/7)\                                                                        
                                                 nt412-413 (7/7)                                                                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------

*H, n = 6; J, n = 7*.

Discussion {#s4}
==========

Cell Culture Studies
--------------------

Although cybrids have identical nuclei and culture conditions, the cell lines with J haplogroup mtDNA exhibit different responses to cisplatin than cybrids with H haplogroup mtDNA. The untreated-J cybrids have significantly increased rates of growth compared to untreated-H cybrids (226 vs. 100%, *P* = 0.001), a finding consistent with a previous study ([@B17]). After treatment with cisplatin, J cybrids show a dose-dependent decrease in cell viability with a 35% decline at 25 μM cisplatin (*P* = 0.044) and 58% decline at 50 μM cisplatin (*P* = 0.0023) compared to the untreated-J cultures. In contrast, H cybrids had non-significant 12% decrease at 25 μM and 38% decline at 50 μM (*P* = 0.05) compared to the untreated-H cybrids. The large decline in cell viability for J cybrids may be because cisplatin, similar to many anti-cancer drugs, is more effective on rapidly growing cells ([@B1]), which is the status of cells containing J mtDNA haplogroup patterns ([@B17], [@B29]). Alternatively, it may be that the differential effects of cisplatin are related to J cybrids having lower oxygen consumption, ATP levels, and mitochondrial membrane potential ([@B17], [@B30]). Interestingly, Ghelli et al. reported that Leber\'s Hereditary Optic Neuropathy (LHON) cell lines with the J haplogroup showed increased sensitivity to 2,5-hexanedione (2,5-HD), a toxic solvent that causes neurological and retinal pathology after exposure ([@B31]).

The ΔΨm decreased significantly in cisplatin-treated-J cybrids but not in cisplatin-treated-H cybrids compared to their untreated controls. The decline in ΔΨm represents early changes that can lead to downstream events such as apoptosis. The release of cytochrome *C* and induction of intracellular apoptosis are mediated through the voltage-dependent anion channel (VDAC) and cisplatin binds to cysteine and methionine sites of the VDAC ([@B32]). The mitochondrial size, shape, and degree of fragmentation can affect binding capacity of BAX, causing changes in mitochondrial outer membrane permeability and apoptosis. The lower ΔΨm levels in cisplatin-treated-J cybrids are consistent with qRT-PCR results showing increased apoptotic gene expressions (*BAX* and *CASP3*) compared to untreated-J cybrids, while the levels in H cybrids did not vary after cisplatin treatment. Our findings show that the mtDNA variants within cells can mediate cisplatin-induced pro-apoptosis events that might contribute to the degrees of toxicity and/or resistance in different individuals.

The cisplatin-treated-H cybrids showed higher ROS levels compared to the cisplatin-treated-J cybrids, which is not completely surprising because the H cybrids utilize OXPHOS, a system that can generate endogenous ROS, while J cybrids use predominantly glycolysis ([@B17]). In addition, there are reports that cisplatin reduces mitochondrial respiration complexes I-IV activity by 15--55%, resulting in higher ROS generation in porcine proximal tubular cells ([@B33]). A similar stimulus of ROS production may occur in H cybrids because of their reliance on the OXPHOS bioenergetics.

The RPE cell line used in this study is non-cancerous (ARPE-19) and cancer cells genomes may respond differently to cisplatin treatment. One side effect of cisplatin therapy is mild to moderate pigmentary retinopathy (abnormalities of the RPE cells) that occurs in some patients but not in others. Our findings demonstrate that *in vitro* the human RPE cells are affected deleteriously by cisplatin treatment but depending upon the mtDNA haplogroup (H vs. J), the responses are differentially expressed. This differential response may contribute to the pigmentary retinopathy found in some patients but lacking in other subjects ([@B7]).

Gene Expression Studies
-----------------------

### Differentially Expressed Genes

We looked at several genes involved with apoptosis: *BAX, BBC3, BCL2L13, CASP9*, and *CASP3*. RNA levels for *BAX* and *CASP3* were upregulated in cisplatin-treated-J cybrids compared to untreated-J cybrids, but the H treated cybrids remained similar to untreated controls. Cisplatin-induced upregulation of *CASP3*, the downstream effector gene for apoptosis, has also been reported in carcinoma cells ([@B34]). Consistent with elevated apoptosis genes, RNA levels for *BAX* were upregulated after cisplatin treatment in J cybrids in comparison to untreated-J cybrids. *BAX* proteins help form porous defects in the mitochondrial outer membrane, leading to release of apoptotic factors ([@B26]). In a mouse model, cisplatin has been shown to induce *BAX* in renal tubular cells ([@B35]). Mice deficient of *BAX* show less cytochrome *C* release from mitochondria, lower levels of renal tubular apoptosis, and increased resistance to cisplatin ([@B35]). Further studies into the mechanisms of *BAX* and *CASP3* upregulation in our cybrids are needed.

*SFRP1* levels were not significantly changed after cisplatin treatment in H cybrids. In contrast, the *SFRP1* levels were lower in cisplatin-treated-J cybrids compared to untreated-J cybrids (*P* = 0.05). This is significant because all nuclei and culture conditions are identical, indicating that cisplatin has different effects on cells depending on whether they contain H or J mtDNA. *SFRP1* is an extracellular inhibitor of the WNT pathway and acts as a tumor suppressor. Lower *SFRP1* levels, as seen in the cisplatin-treated-J cybrids, can be associated with resistance to cisplatin and poorer patient survivability ([@B36]).

The *CDKN1/p21* gene levels were higher after cisplatin treatment in H cybrids compared to untreated-H cybrids (*P* = 0.002). In contrast, the *CDKN1/p21* gene levels were not changed in the J cybrids after treatment (*P* = 0.12). Higher levels of *CDKN1/p21* are significant because of its role in cellular responses to DNA damage and cell cycle arrest. Overexpression of *p21* inhibits colony formation of tumor cells ([@B37]). In addition, Duensing et al. reported that abnormal expression of *p21* is associated with chromosomal instability as seen in tumor cells ([@B38]). Usually, induction of *CDKN1A* mRNA level is dependent on *Tp53* ([@B39]) but in our H and J cybrids, the *Tp53* expression levels were not changed in response to cisplatin treatment (data not shown). This suggests that upregulation of *CDKN1A/p21*, as seen in cisplatin-treated-H cybrids, is independent of *Tp53* expression.

There was an interesting disparity in the J and H cybrids after cisplatin treatment. The untreated-H and J cybrids had similar expression levels for *ABCC1, DHRS2/HEP27*, and *EFEMP1* but after cisplatin-treatment, the treated-J cybrids showed lower expression levels compared to the untreated-J cybrids (*P* = 0.02, *P* = 0.02, and *P* = 0.04, respectively), while the cisplatin-treated-H were similar to the H-untreated. After cisplatin treatment, higher expression levels of *DHRS2/HEP27* were found in the cisplatin-treated-H cybrids compared to the cisplatin-treated-J cybrids. An accumulation of DHRS2/HEP27 pre-protein in the mitochondria matrix can lead to mature DHRS2/HEP27 translocating to the nucleus, where it eventually binds and inhibits MDM2, leading to stabilization of the *Tp53* pathway and indirect tumor repressor functions within the cell. Higher levels of *DHRS2/HEP27* gene expression in cisplatin-treated-H cybrids could be associated with MDM2-mediated breakdown of the *Tp53* gene, and ultimately stabilization of cellular homeostasis ([@B40]).

*ABCC1* functions as a transporter, mediates export of drugs from the cytoplasm, and also confers resistance to anti-cancer drugs ([@B41], [@B42]). In osteosarcoma cells, *ABCC1* was the most relevant transporter associated with drug resistance, along with the *ABCB1* transporter ([@B27]). After cisplatin treatment, up-regulations of *ABCC1* and *EFEMP1* were found in the cisplatin-treated-H cybrids compared to the cisplatin-treated-J cybrids. The higher *ABCC1* levels in H cybrids suggest these cells may be more likely to become resistant to anticancer drugs than cells with J mtDNA. If our *in vitro* findings represent *in vivo* events, then patients with J haplogroup mtDNA might be less likely to become resistant to anticancer drugs while the H haplogroup patients are more likely. *EFEMP1* is a gene associated with the production of EGF-containing fibulin-like extracellular matrix protein 1. Overexpression of this gene has been linked to *in vivo* and *in vitro* chemotherapeutic drug resistance in cases used to treat glioblastoma tumor growth. The higher *EFEMP1* gene expression levels in H cybrids may be a precursor to drug resistant cybrid cells treated with cisplatin ([@B43]). Future studies should be conducted to determine if there is correlation between mtDNA haplogroup patterns and cisplatin resistance.

Based upon our findings, it is apparent that after cisplatin treatment, cells containing J haplogroups (Northern European) variants show different biological behavior and gene expression patterns compared to those cells possessing the Southern European H haplogroup mtDNA. At this time, it is not clear how the H vs. J mtDNA profiles influence the nuclear gene expression in cybrids. The effects may be not strictly related to the haplogroup mtDNA as a whole but rather the presence of specific SNPs, which in this case, are defining the J haplogroup. For example, the m10398A\>G polymorphism (*MT-ND3*, ALA-THR) defines the J haplogroup ([www.MitoMap.org](http://www.MitoMap.org)). The m10398A\>G has been associated with breast cancer in African-American women ([@B44]), although no association was found in another study ([@B45]). Another J haplogroup-defining SNP, m13708G\>A (*MT-ND5*, ALA-THR), has also been associated with breast cancer ([@B46]). Even though these SNPs were located in different mtDNA encoding genes, each of these has an amino acid change from Alanine, a non-polar, neutral amino acid to the polar, neutral Threonine, which could change bonding and function of proteins. In contrast, when mtDNA from H cybrids were sequenced, there were no mtDNA variant/mutations that have been associated with human cancers ([@B47]). One can speculate that one or all of these J haplogroup-defining SNPs can contribute to changes in retrograde signaling between the mtDNA and nuclear genomes. While further work is needed to identify mechanisms and pathways, our findings support the hypothesis that an individual\'s mtDNA background can contribute to the response to cisplatin, which is important for the drug\'s efficacy, level of side effect and development of resistance.

In summary of the gene expression studies, the effects of cisplatin on gene expression fell into five categories ([Figure 4](#F4){ref-type="fig"}). The first category was that cisplatin did not change gene expression in either cisplatin-treated-J or cisplatin-treated-H cybrids (*MAPK8, MAPK10, FOXM1, BBC3, BCL2L13, CASP9, ALK1, BRCA1, EGFR, ERBB2, ERCC1, CDK2, TP53, BMI1*, and *KAT5/TIP60*). The second category was that cisplatin-treated-J cybrids were downregulated (*SFRP1*) and the third category showed upregulation (*CYP51A, BAX*, or *CASP3*) compared to the untreated-J cybrids. The fourth category was that cisplatin-treated-H cybrids showed increased transcription of *CDKN1A/p21* gene compared to untreated-H cybrids, while the J cybrid levels were not affected. Finally, that cisplatin-treated-J cybrids showed lower levels of gene expression compared to cisplatin-treated-H cybrids (*DHRS2/HEP27, ABCC1*, and *EFEMP1*).

![Schematic showing the changes in gene expression levels for H and J cybrids after cisplatin treatment fall into different categories: (1) there are no differences in the expression levels between the untreated and cisplatin-treated cybrids (*MAPK8, MAPK10, FOXM1, BBC3, BCL2L13, CASP9, ALK1, BRCA1, EGFR, ERBB2, ERCC1, CDK2, TP53, BMI1*, and *KAT5/TIP60*). (2) Lower expression levels of *SFRP1* are found in the cisplatin-treated-J cybrid compared to the untreated-J cybrid; (3) Upregulation of *CYP51A, BAX*, and *CASP3* in the cisplatin-treated-J cybrids compared to the untreated-J cybrids; (4) Higher levels of *CDKN1A/P21* are found in the cisplatin-treated H cybrids compared to the untreated H cybrids; (5) The H-cisplatin cybrids showed higher expression levels of *DHRS2/HEP2, ABCC1*, and *EFEMP1* compared to the cisplatin-treated-J cybrids.](fonc-09-00640-g0004){#F4}

Sequencing of the Entire mtDNA
------------------------------

NGS analyses performed on the mtDNA from each of the H and J cybrids showed that the majority of the SNPs identified were haplogroup defining. The private SNPs (non-haplogroup defining), unique SNPs (not listed in [www.MitoMap.org](http://www.MitoMap.org)), and heteroplasmy SNPs were found in individual cybrids and not throughout all of the H or J cybrids. This suggests that the differential retrograde signaling between the H and J mtDNA haplogroups is due to the accumulation of the haplogroup defining SNPs rather than a single mutation or private SNP. Our findings are consistent with the sequencing results from another cybrid study that used allelic discrimination and Sanger sequencing to identify the mtDNA haplogroups ([@B48]). The advancement of NGS for mtDNA analyses allowed deep sequencing in ranges from 1,000 to 100,000 with an average depth of 30,000 so that low level heteroplasmy could be reliably identified. In addition, our method allowed for both strands of mtDNA to be independently sequenced and in both directions, which helps to distinguish between artifact and low level heteroplasmy. The mechanisms of retrograde signaling for the different mtDNA haplogroups are under investigation and likely include as of yet unidentified pathways.

Comparison of GG Stretches Within the MT-DLoop Region
-----------------------------------------------------

Our previous report related to the *MT-DLoop* region showed the greatest SNP variations in J vs. H mtDNA were in (a) the nucleotides (np) 263--461 region; (b) Conserved Sequence Block 2 region (np 299-315); (c), H Strand Origin region (np 110-441); (4) Hypervariable Segment 2 region (np 57-372); and (5) the np 310--321 region that had high variability with C insertions ([@B48]). However, H and J mtDNA had similar total numbers of CpG and non-CpG methylation sites in the *MT-DLoop*. The mtDNA is a target for epigenetic modifications and altered methylation patterns have been associated with diseases, drug exposure and aging ([@B49]--[@B51]). However, the degree of mtDNA methylation is still controversial and some have suggested that the methylation levels are very low to absent in mtDNA ([@B52], [@B53]). Cisplatin causes DNA damage by adduct formation at intra-strand d(GpG) crosslink sites. The rate of DNA adduct formation increases in acidic conditions ([@B28], [@B54]) and higher numbers of GG stretches may lead to more binding of cisplatin to the mtDNA. Importantly, our previous bioenergetic studies showed that J cybrids preferentially use glycolysis and have higher levels of extracellular acidification rates (ECAR) than the cybrids with H haplogroup mtDNA ([@B48]), leading to the possibility that the H and J mtDNA *MT-DLoop* may possess different levels of GG sites. However, we found that within the *MT-Dloop* regions, the numbers of GG stretches (GG, GGG, GGGG, and GGGGG) were similar in H and J cybrids. Therefore, the environmental microenvironment may be playing a bigger role in cisplatin-related adduct formation rather than the numbers of GG stretches in the mtDNA but further work is needed to clarify this question.
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